The aims of CPIA are focused on abiding by the Constitution, laws, regulations and polices of P.R.C, undertaking industry management work entrusted by the government, serving as a bridge between the government and enterprises, serving its members & protecting their legal rights & interests. expressing the opinions of the members of the government, assisting the government to make industrial policies, promoting the healthy development of the pharmaceutical industry in China.

CPIA offers good quality service to its members and has completed a number of projects related to industry surveys and research since its establishment. CPIA also played a role as communicator between the government and the members, expressed opinions about industry polices and proposed constructive suggestions to the government. Moreover, CPIA collected valuable technical, economic, marketing, policy related information and materials of the industry from China and abroad and supplied them to its members. CPIA also carried out wide range consultancy services and initiated technical transfer programs and activities, which give considerable benefits to its members. Recently CPIA organized workshops, seminars to coordinate direct dialogues between the government and member companies focusing on relevant hot topics of drug bidding policies, drug pricing, national drug list for basic medical insurance, drug registration and drug reimbursement. What's more, CPIA has set up a system of conducting regular dialogue with the Price Dept. of National Development and Reform Commission, the Medical Insurance Dept. of Ministry of Labor and Social Security, and the Drug Registration Dept. of State Food and Drug Administration. These activities enhanced the understanding between the government and the enterprises and also helped the members of CPIA adequately carry out drug laws, regulations and policies of the government. Entrusted by China Federation of the Industrial Economics, CPIA recommended concerned experts to discuss MOC (Ministry of Commerce)'s List of the Technologies Encouraged to Import, Technologies Restricted to Import, Technologies Forbidden to export.

CPIA explored nongovernmental contacts and exchanges with foreign counterparts, established good relationship with pharmaceutical industry associations from SouthEast Asia, West Europe, North Europe as well as Taiwan Region, Japan, South Korea, and India.

The work of CPIA has been effective and fruitful and CPIA has been supported by its members and appraised by the government. It was honored as “Excellency Rewards for Industrial Association” in the year of 1994, 1998 and 2003. It was also awarded a medal as “SARS Fighters” as an advanced national industrial association by the Ministry of Civil Affairs.

CPIA has always been led by pharmaceutical industry senior executives and entrepreneurs. The management team of CPIA was elected in April 2004 and the sixth session of the leadership is as follows: Chairman, Ms Zheng Hong, the Chairman of China National Pharmaceutical Group Corp; Executive Chairman, Mr. Li Shunnian, also the 3rd, 4th and 5th Chairman of CPIA; Honorary Chairman, Mr. Zheng Xiaoyu, the Director General of State Food and Drug Administration; Honorary Chairman, Mr. Gu Jiaqi, the Senior Vice Chairman of China Federation of Industrial Economics; Specially Invited Advisor, Mr. Yu Mingde, the Executive Chairman of China Pharmaceutical Enterprise Management Association.

The other executives and vice Chairman of CPIA are from top executives the prominent pharmaceutical companies, including large and medium sized stateowned companies and nongovernmental enterprises. Some are also from senior management of famous sinoforeign pharmaceutical joint ventures, commercial corporations as well as top leaders of regional pharmaceutical industry associations. As China further improves its market environment and deepens its economic reform, there is a wider space for CPIA to develop its business and it is playing a more important role in the industry. With the improvement of the CPIA service, CPIA will engage more activities in pharmaceutical companies' restructuring and reorganizations, technical transfer, research innovations, in discussing the sustained growth of the industry, two markets and two kinds of resources. Under the support of all its members, its working departments and subsidiaries, the Council directors of CPIA, regional pharmaceutical industry associations and organizations of various circles in China, CPIA shall continue to provide quality service, to explore and do more solid work so as to contribute to the sustained growth of China's pharmaceutical industry and the improvement of people's health.